Used as a key intermediate in the synthesis of Janus kinase (JAK) inhibitors, particularly in the development of targeted therapies for inflammatory and autoimmune diseases such as rheumatoid arthritis and psoriasis. Its structural features enable selective modulation of JAK enzyme activity, contributing to reduced cytokine signaling and inflammation. The compound’s design supports improved pharmacokinetic properties, including metabolic stability and oral bioavailability, making it valuable in optimizing drug candidates for clinical use.